gorodenkoff/iStock via Getty Images Evotec ( NASDAQ: EVO ) ADRs quickly rose 14% on a report that Halozyme Therapeutics ( HALO ) has expressed takeover interest. Halozyme has recently expressed interest in purchasing Evotec for ~€11 per share, according to a Bloomberg report on Thursday, which cited people familiar with the matter..
